This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

First Manhattan Announces That Anthony Zook Has Agreed To Serve As Vivus CEO If Its Director Nominees Are Elected

Stocks in this article: VVUS

First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.9 percent of the outstanding shares of VIVUS, Inc. (“Vivus”) (NASDAQ: VVUS), today announced that Anthony (“Tony”) Zook has agreed to serve as Vivus’ CEO if FMC’s director nominees are elected at the upcoming Vivus shareholder meeting on July 15, 2013.

Mr. Zook is a world-class executive who has held multiple senior leadership positions at some of the world’s leading pharmaceutical companies, most recently as the Executive Vice President for Global Commercial Operations at AstraZeneca, a position he held until February 2013. At AstraZeneca, Mr. Zook played leadership roles, both in the US and globally, in the market delivery of several blockbuster products, each with sales in excess of $1 billion, including Nexium, Crestor, Pulmicort Respules, Seroquel, Toprol XL and Symbicort. He also helped manage the commercial integration of Astra and Zeneca to help create AstraZeneca, and served as President of MedImmune, AstraZeneca’s largest biotech acquisition, from November 2008 to December 2009.

As Executive Vice President of Global Commercial Operations at AstraZeneca, Mr. Zook was responsible for commercial activities worldwide that led to the delivery of a $28 billion dollar business, and was responsible for approximately 28,000 people with operations in more than 85 countries. Among other accomplishments, Mr. Zook led AstraZeneca’s commercialization team on all partnering activities with Bristol Myers Squibb for Onglyza and Forxiga, oral Type 2 diabetes agents that are highly relevant to a market directly adjacent to the obesity market.

Prior to serving as EVP of Global Commercial Operations, Mr. Zook held a series of increasingly senior positions at AstraZeneca, including President of its U.S. business, Executive Vice President of Global Marketing, Executive Vice President and CEO of North America, and President of MedImmune.

“Vivus presents an exciting challenge and enormous opportunity,” said Tony Zook. “I was attracted to Vivus because Qsymia has the potential to improve the quality of life for millions of people. While there is still much work to be done to commercialize Qsymia, I am confident that I can work closely with the talented employees of Vivus and the independent board to bring an exciting medicine to people who can benefit from it and put Vivus on a trajectory of growth and value creation.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs